You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】美團上周急衝後續高位徘徊 即市資金追牛 港交所再挑戰280元 美團最貼牛59878 熊54379/ 港交牛53765 熊51186/ 中藥購26709 熊53306
阿思達克 06-01 10:32
美國總統特朗普稱,正指示政府官員展開廢除給予香港特殊待遇的程序,但未有提及取消早前中美達成的首階段貿易協議,美股上周五走勢波動,道指收報25383點,跌17點(或0.1%)。恆指上周五收報22961點,跌171點(或0.7%),連跌三個交易日,全個五月累跌1682點(或6.8%)。今早大升近800點,升穿23700點。恆指好倉(牛證及認購權證)上周五淨流入456萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流出逾4100萬元,反映小量資過夜金趁大市下跌博反彈。上周五恆指牛證街貨重貨區為收回價22500至22599點,而熊證街貨重貨區為收回價23700至23799點。

美團點評(03690)儘管被聯合創辦人王慧文減持,但受惠正式上線信用支付產品「美團月付」,以及MSCI上周五收市後調整組合,帶動美團上周五在收市競價時段抽高,以全日高位收市,報146.7元,急漲7.1%,再創歷史新高,成交超過210億元,是最活躍港股。美團自公布首季業績後持續跑贏大市,上周急漲逾23%,今早則略為回軟,下試145元水平。美團上周五錄3.79億元淨流出,輪證資金流方面,逾1000萬元在上周五淨流出其好倉,淡倉同日則有逾2600萬元淨流入。今早資金追入全場最貼牛59878。

據報港交所(00388)上周五已批准京東及網易的上市申請,加上港交所近日奪得MSCI授權,將在香港推出37隻追蹤MSCI亞洲及新興市場指數的期貨及期權產品,刺激港交所上周五逆市向好,曾升近1.8%至274.4元,收市仍企270元之上。今早再升約3%,高位逼近280元。上周五分別有近380萬和160萬元淨流入其好倉和淡倉。

吉利汽車(00175)以每股10.8元配售6億股,以增強集團財務狀況及提供營運資金,拖累股價上周五急挫9.5%,收報10.6元,失守配股價。今早反彈近3%,上試11元水平。吉利上周五錄近4億元北水淨流入。輪證資金流方面,上周五有744萬元淨流入其好倉,為當日最多資金淨流入的相關資產,淡倉同日則有130萬元淨流出。

中國生物製藥(01177)首季度收入62.22億人民幣,純利8.62億元人民幣,按年微增,績後獲追捧,股價上周五飆7.4%,重上12.2元。今早漲超過9%,升至近13.4元,創兩年高位。上周五有近240萬元淨流出其好倉,淡倉同日則有約80萬元淨流入。

瑞通相關認股證之選擇:

恆指輕微價外、中短期購25622,行使價:25920點,2020年10月到期,實際槓桿:11.5倍

恆指貼價、中年期沽27866,行使價:22000點,2020年12月到期,實際槓桿:6倍

美團貼價、中年期購11454,行使價:152.78元,2020年12月到期,實際槓桿:4.8倍

美團價外、中年期沽11204,行使價:110元,2020年12月到期,實際槓桿:5.1倍

港交輕微價外、中短期購12171,行使價:299.88元,2020年10月到期,實際槓桿:8.4倍

港交貼價、短期沽20438,行使價:268.8元,2020年7月到期,實際槓桿:8.4倍

吉利輕微價外、中年期購26982,行使價:11.86元,2020年12月到期,實際槓桿:4.1倍

中藥輕微價外、中年期購26709,行使價:14.28元,2020年12月到期,實際槓桿:3.9倍

阿里輕微價外、中短期購23447,行使價:222.88元,2020年9月到期,實際槓桿:9.1倍

阿里輕微價外、短期沽23203,行使價:182.08元,2020年7月到期,實際槓桿:11.6倍

新地輕微價外、中年期購11304,行使價:103.8元,2020年12月到期,實際槓桿:7.4倍

瑞通相關牛熊證之選擇:

恆指熊證51619,收回價:24238點,槓桿比率:27.6倍

美團全場最貼牛證59878,收回價:130.499元,槓桿比率:7.6倍

美團熊證54379,收回價:159.9元,槓桿比率:7.9倍

港交牛證53765,收回價:254.8元,槓桿比率:10.2倍

港交熊證51186,收回價:287.9元,槓桿比率:21.9倍

吉利牛證56409,收回價:9.9元,槓桿比率:6.2倍

吉利熊證69971,收回價:13.2元,槓桿比率:3.4倍

中藥牛證61534,收回價:9.9元,槓桿比率:3.4倍

中藥熊證53306,收回價:13.9元,槓桿比率:8.4倍

友邦牛證58172,收回價:58.5元,槓桿比率:8倍

友邦熊證66579,收回價:72.99元,槓桿比率:7.4倍

新地熊證69445,收回價:107.8元,槓桿比率:5.1倍

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account